Recruiting

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension. 3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.

ClinicalTrials.gov IDNCT06093932

PhasePHASE4

Enrollment100

SponsorXiyuan Hospital of China Academy of Chinese Medical Sciences

Age35 Years – 65 Years

SexALL

I'm interested View official listing

Conditions studied

Hypertension,Essential

About this study

Interventions

Drug: Songling Xuemaikang Capsules — 3 capsules at a time, three times a day, duration: 12 weeks
Behavioral: Lifestyle intervention — everyday, duration: 12 weeks
Drug: Placebo — 3 capsules at a time, three times a day, duration: 12 weeks

Primary outcomes

Change from Baseline in the Mean 24h Systolic Blood Pressure at 4,12 weeks (Baseline and Week 4,12)

Eligibility information

Inclusion Criteria: * Age between 35-65 years old, male or female; * Grade 1 essential hypertension; * Taking no antihypertensive drugs or taking antihypertensive drugs irregularly in the past ; * Sign the informed consent; Exclusion Criteria: * Significant liver and kidney dysfunction, ALT and AST upper the twice of normal range, Scr≥2.0mg/dl, eGFR\<60ml/(min·1. 73m2); * Gastrointestinal diseases, which may affect drug absorption; * Be allergic to the clinical trial medicine; * Pregnant or breastfeeding women, men who plan to give birth within half a year; * Combined with other serious primary diseases or malignant tumors; * Hyperlipidemia with or without taking lipid-lowering drugs; * Combined with left ventricular hypertrophy, ABI \< 0.9, CIMT ≥ 0.9mm or atherosclerotic plaque; * Hypertensive comorbidities (cerebrovascular disease, other cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, diabetes); * Other serious conditions in which is not fit for the study.

Study locations

Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing Municipality 100091 China
Suzhou Hosptial of Traditional Chinese Medicine, Suzhou, Jiangsu 215002 China
Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250013 China
China Academy of Chinese Medical Sciences Xiyuan Hospital Jining Hospital, Jining, Shandong 272000 China
China Academy of Chinese Medical Sciences Xiyuan Hospital Shanxi Hospital, Taiyuan, Shanxi 030024 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-27.